Pierre-Joseph Pelletier
1788-1842 · Француз · Фармакология
Французский химик, чьё выделение растительных алкалоидов (хинин, стрихнин, кофеин, бруцин) положило начало методологии экстракции чистых соединений, которая впоследствии была применена Хейкрафтом и Якоби для получения гирудина из слюнных желёз медицинской пиявки.
Профиль
- Годы жизни
- 1788-1842
- Национальность
- French
- Эпоха
- XIX век
- Основная область
- Фармакология
Аффилиации
- École de pharmacie de Paris (Professor and later Director)
- Académie des sciences, Paris (member, 1840)
- Pelletier-Caventou quinine manufactory, Paris
Ключевой вклад
- Co-isolated quinine from Cinchona bark with Joseph Bienaimé Caventou in 1820 — a milestone in the chemistry of natural products and the foundation of modern antimalarial therapy.
- Co-isolated strychnine, brucine, veratrine, and caffeine in the early 1820s, establishing the conceptual category of the alkaloid as a class of nitrogen-containing plant secondary metabolites with potent physiological action.
- Developed the methodological template — solvent extraction, salt formation, recrystallization — that became the standard approach to isolating active principles from biological tissues throughout the nineteenth century.
- Co-founded the first industrial-scale quinine manufactory in Paris, demonstrating that pure-compound natural-product chemistry could supply therapy at clinical scale.
- Served as professor of natural history of medicines at the École de pharmacie de Paris and exercised wide influence on the next generation of French chemists.
Важность для гирудотерапии
Pierre-Joseph Pelletier never worked on leeches and never published on hirudin — yet his methodological contributions are foundational to the entire molecular era of hirudotherapy. The technique by which John Berry Haycraft isolated hirudin in 1884 (saline perfusion, protein precipitation, dialysis, lyophilization) and by which Karl Jacoby industrialized hirudin extraction in 1902 (large-scale tissue maceration, salt fractionation, repeated recrystallization) descends directly from the natural-product chemistry that Pelletier and his collaborator Joseph Caventou pioneered in Paris between roughly 1817 and 1825. Without this methodological tradition, the leech salivary gland would have remained a black box of unspecified bioactive secretions. The specific intellectual leap that Pelletier embodied was the move from describing the actions of a crude botanical or biological preparation (cinchona bark, opium, leech saliva) to isolating the single chemical principle responsible for those actions. Before Pelletier, pharmacology was largely the study of mixtures; after Pelletier, it became the study of pure compounds with definable molecular structure. This conceptual reorientation is precisely what made hirudin meaningful as a research subject: Haycraft did not merely show that leech saliva inhibited clotting (a fact known anecdotally for centuries), he isolated a discrete protein that did so reproducibly and which could in principle be characterized further. The American Society of Hirudotherapy includes Pelletier in its biographical registry as the patron of the natural-product chemistry tradition from which modern hirudin and leech-derived drug discovery descend. Every recombinant hirudin product on the market today, every Factor Xa inhibitor descended from antistasin or ghilanten, every destabilase research program, traces its methodological lineage through Markwardt's 1957 purification, through Jacoby's 1902 extraction, through Haycraft's 1884 isolation, back to Pelletier and Caventou's quinine in 1820. He is the indirect intellectual ancestor of the entire leech-pharmacology field.
Ключевые публикации
- Recherches chimiques sur les quinquinas (with J. B. Caventou) · Annales de chimie et de physique (1820)
- Sur un nouvel alcali végétal (la strychnine) trouvé dans la fève de Saint-Ignace, la noix vomique, etc. · Annales de chimie et de physique (1819)
- Note sur la caféine · Journal de pharmacie (1821)
Внешние ресурсы
Связанные деятели
John Berry Haycraft
1857-1922 · Британец (шотландец)
Эдинбургский физиолог, который в 1884 году открыл гирудин, основав современную молекулярную фармакологию слюны пиявок.
Fritz Markwardt
1924-2011 · Немец (восточногерманский / ГДР)
Грейфсвальдский фармаколог, который в 1957 году очистил гирудин до гомогенного состояния, охарактеризовал его механизм и заложил всю научную основу для современного класса лекарственных препаратов — прямых ингибиторов тромбина.
John W. Fenton II
1937-2007 · Американец
Биохимик из Медицинского колледжа Олбани, чья очистка и характеристика рекомбинантного гирудина в конце 1980-х годов позволила компании Hoechst Marion Roussel / Behringwerke разработать лепирудин (Рефлюдан), первый одобренный FDA прямой ингибитор тромбина.
John M. Maraganore
1956- · Американец
Основатель Biogen / The Medicines Company, который разработал бивалирудин (Angiomax) — рационально сконструированный синтетический аналог гирудина, ставший стандартным прямым ингибитором тромбина для чрескожного коронарного вмешательства.